# OnCo record raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant" ;
  schema:name "Raised cholesterol and triglycerides, and weight gain, on lorlatinib, bexarotene and elacestrant"@en ;
  schema:alternateName "hyperlipidaemia on lorlatinib"@en, "hyperlipidemia on lorlatinib"@en, "high cholesterol on lorlatinib"@en, "high triglycerides on lorlatinib"@en, "hypertriglyceridaemia on bexarotene"@en, "statins with lorlatinib"@en, "weight gain on lorlatinib"@en, "dyslipidaemia on elacestrant"@en ;
  schema:description "Lorlatinib raises cholesterol and triglycerides (blood fats) in most people, often within weeks, and about three in ten gain weight. Bexarotene raises triglycerides sharply; elacestrant less often. Blood tests come before and during treatment, and a statin or similar medicine is often added. On lorlatinib or bexarotene, tell your team straight away about tummy or back pain, or being sick."@en ;
  schema:url <https://onco.cc/protocols/raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  onco:related <https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/>, <https://onco.cc/protocols/diet-alcohol-and-weight-during-cancer-treatment/>, <https://onco.cc/protocols/hyperglycaemia-on-pi3k-akt-mtor-inhibitors/>, <https://onco.cc/protocols/anticancer-drug-interaction-review/>, <https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/>, <https://onco.cc/protocols/cognitive-and-mood-effects-on-lorlatinib-and-avapritinib/> ;
  onco:drugs <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/bexarotene/>, <https://onco.cc/drugs/elacestrant/> ;
  onco:terms <https://onco.cc/terms/ctcae-grading/>, <https://onco.cc/terms/dose-modification/> .
